Article

Mark Zitter, MBA, Discusses Oncology Pathways

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs.

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs. However, Zitter says that over the next year or so, pathways will not be the dominant factor in oncology management.

Related Videos
Lawrence Eichenfield, MD, FAAD
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Douglas Flora, MD, FACCC
Molly Dean, MSW, Siftwell
Dr Xin Hu
Bridgette J. Picou, LVN, ACLPN, The Well Project
Priscilla Tsondai, MD, MPH, IAS/CIPHER
Mia Moore, PhD, Fred Hutch Cancer Center
rachel rohaidy
Related Content
Medical data-everythingpossible-stock.adobe.com
March 13th 2025

As Claims Denials Surge, AI and Data-Driven Insights Equip Clinicians, Hospitals to Fight Back

Giuliana Grossi Pearl Steinzor
As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in shaping the future of patient care, according to experts from Komodo Health and SmarterDx.
Managed Care Cast Logo
February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS
On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Sharon Hesterlee, PhD
March 13th 2025

Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025

Kyle Munz Sharon Hesterlee, PhD
Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
managed care cast logo
February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Lynae Darbes, PhD, University of Michigan School of Nursing
March 12th 2025

Couples Counseling Key to HIV Prevention and Maternal Care

Maggie L. Shaw Lynae Darbes, PhD
Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples living in Kenya.
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025

Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH

Maggie L. Shaw Amy Colson, MD, MPH
New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo